Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | CDC25B | P30305 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088037 | 0.89 | HSPA5 (0.36) | HSPA5TNK2PDE2ARIPK1PTPN1 | |
| SCHEMBL10082719 | 0.89 | HSPA5 (0.36) | HSPA5TNK2PDE2ARIPK1PTPN1 | |
| SCHEMBL12393393 | 0.89 | HSPA5 (0.36) | HSPA5TNK2PDE2ARIPK1PTPN1 | |
| SCHEMBL31725287 | 0.83 | PDE2A (0.38) | HSPA5TNK2PDE2ARIPK1 | |
| SCHEMBL31063739 | 0.82 | PDE2A (0.37) | HSPA5TNK2PDE2APTPN1CDC25B | |
| SCHEMBL12393373 | 0.82 | PDE2A (0.37) | HSPA5TNK2PDE2APTPN1CDC25B | |
| SCHEMBL27086454 | 0.82 | PDE2A (0.37) | HSPA5TNK2PDE2APTPN1CDC25B | |
| SCHEMBL12243141 | 0.82 | PDE2A (0.37) | HSPA5TNK2PDE2APTPN1CDC25B | |
| SCHEMBL20380380 | 0.82 | HSPA5 (0.37) | HSPA5TNK2PDE2A | |
| SCHEMBL12393217 | 0.82 | HSPA5 (0.35) | HSPA5TNK2PDE2ARIPK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | HSPA5 4513/4885TNK2 594/4885PDE2A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.